Chicago, October 30, 2014 - The Society of Thoracic Surgeons (STS) has released new clinical practice guidelines for treating cancer of the esophagus and gastroesophageal junction (area where the esophagus meets the stomach).
The guidelines, published in the November 2014 issue of The Annals of Thoracic Surgery, include nine evidence-based recommendations that address issues related to multimodality care, including neoadjuvant therapy (chemotherapy and radiation therapy given prior to surgery). The goal of this therapy is to reduce the extent of cancer before an operation to maximize the chance of obtaining a cure.
"Despite the widespread enthusiasm for multimodality therapy and the myriad of its aspects, currently available data for each component of care are not truly definitive," said Guideline Task Force Chair, Alex G. Little, MD, from the University of Arizona in Tucson. "The recommendations included in our document are guidelines, not mandates, but we feel they identify best current practices."
STS' Clinical Practice Guidelines are intended to assist physicians and other health care providers in clinical decision making by describing a range of generally acceptable approaches for the diagnosis, management, or prevention of specific diseases or conditions. Prior to publication, each guideline undergoes an intense peer-review process, which provides critical, unbiased scientific assessment of the document and helps to identify future areas of investigation.
The Society has 18 current clinical practice guideline documents, including one released in July 2013 on factors affecting the diagnosis and treatment of localized esophageal cancer. Future guidelines on esophageal cancer will address esophageal resection and early stage disease.
"Understanding that technology continues to advance and even biological behavior can be modified, patient care decisions should be made by a multispecialty group with input from all relevant specialists," said Dr. Little.
Notes for editors
"The Society of Thoracic Surgeons Practice Guidelines on the Role of Multimodality Treatment for Cancer of the Esophagus and Gastroesophageal Junction" (10.1016/j.athoracsur.2014.07.069)The Annals of Thoracic Surgery published by Elsevier. http://www.
Full text of the article is available to credentialed journalists upon request; contact Cassie McNulty email@example.com at +1 312 202 5865
About The Annals of Thoracic Surgery The Annals of Thoracic Surgery is the official journal of the Society of Thoracic Surgeons (STS) and the Southern Thoracic Surgical Association. Founded in 1964, The Society of Thoracic Surgeons is a not-for-profit organization representing more than 6,800 cardiothoracic surgeons, researchers, and allied health care professionals worldwide who are dedicated to ensuring the best possible outcomes for surgeries of the heart, lung, and esophagus, as well as other surgical procedures within the chest. The Society's mission is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions -- among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey -- and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media Relations Manager STS
+1 312 202 5865